EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
EyePoint Pharmaceuticals : PAVIA Topline Data Conference Call Presentation marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
EyePoint Pharmaceuticals shares fell more than 26% in premarket activity Monday after the company said a trial of its potential diabetes treatment Duravyu failed to meet the primary endpoint of.